CLSD - Clearside Biomedical, Inc.
IEX Last Trade
0.8979
0 0%
Share volume: 400
Last Updated: Thu 26 Dec 2024 04:28:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.82%
PREVIOUS CLOSE
CHG
CHG%
$0.90
0.00
0.00%
Fundamental analysis
38%
Profitability
25%
Dept financing
48%
Liquidity
75%
Performance
40%
Performance
5 Days
6.50%
1 Month
-13.98%
3 Months
-17.05%
6 Months
-25.68%
1 Year
-10.67%
2 Year
-18.51%
Key data
Stock price
$0.90
DAY RANGE
$0.89 - $0.90
52 WEEK RANGE
$0.92 - $2.12
52 WEEK CHANGE
-$21.27
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: George M. Lasezkay
Region: US
Website: clearsidebio.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: clearsidebio.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Clearside Biomedical, Inc. focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprchoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX and CLS-301, an integrin inhibitor suspension for macular degeneration.
Recent news